These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Update on aspirin in the treatment and prevention of cardiovascular disease. Hennekens CH Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736 [TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Bartolucci AA; Howard G Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176 [TBL] [Abstract][Full Text] [Related]
4. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114 [TBL] [Abstract][Full Text] [Related]
5. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466 [TBL] [Abstract][Full Text] [Related]
6. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Berger JS; Brown DL; Becker RC Am J Med; 2008 Jan; 121(1):43-9. PubMed ID: 18187072 [TBL] [Abstract][Full Text] [Related]
7. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Hennekens CH; Schneider WR Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910 [TBL] [Abstract][Full Text] [Related]
8. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. Berger JS; Krantz MJ; Kittelson JM; Hiatt WR JAMA; 2009 May; 301(18):1909-19. PubMed ID: 19436018 [TBL] [Abstract][Full Text] [Related]
9. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947 [TBL] [Abstract][Full Text] [Related]
10. Aspirin and primary cardiovascular prevention. Uncertain balance between benefits and risks. Prescrire Int; 2010 Nov; 19(110):258-61. PubMed ID: 21284360 [TBL] [Abstract][Full Text] [Related]
11. An update on aspirin in the primary prevention of cardiovascular disease. Eidelman RS; Hebert PR; Weisman SM; Hennekens CH Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112 [TBL] [Abstract][Full Text] [Related]
12. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320 [TBL] [Abstract][Full Text] [Related]
13. [Primary prevention of cardiovascular diseases with acetylsalicylic acid]. Waltering A; Hemkens L; Florack C Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615 [TBL] [Abstract][Full Text] [Related]
14. Aspirin for primary prevention: yes or no? Selak V; Elley CR; Wells S; Rodgers A; Sharpe N J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297 [TBL] [Abstract][Full Text] [Related]
15. Aspirin for primary prevention of cardiovascular disease events. Nemerovski CW; Salinitri FD; Morbitzer KA; Moser LR Pharmacotherapy; 2012 Nov; 32(11):1020-35. PubMed ID: 23019080 [TBL] [Abstract][Full Text] [Related]
16. Aspirin for primary prevention of myocardial infarction: what is the evidence? Kappagoda T; Amsterdam E J Cardiopulm Rehabil Prev; 2012; 32(1):1-8. PubMed ID: 21946421 [TBL] [Abstract][Full Text] [Related]
17. Antiplatelet therapy in the prevention of ischaemic stroke. Verry M; Panak E; Cazenave JP Nouv Rev Fr Hematol (1978); 1994 Jun; 36(3):213-28. PubMed ID: 7971242 [TBL] [Abstract][Full Text] [Related]
18. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262 [TBL] [Abstract][Full Text] [Related]
19. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Stavrakis S; Stoner JA; Azar M; Wayangankar S; Thadani U Am J Med Sci; 2011 Jan; 341(1):1-9. PubMed ID: 21191260 [TBL] [Abstract][Full Text] [Related]
20. Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin. McGrath E; O'Conghaile A; Eikelboom JW; Dinneen SF; Oczkowski C; O'Donnell MJ Cerebrovasc Dis; 2011; 32(1):22-7. PubMed ID: 21576939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]